Deerfield Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Deerfield Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$10	–	119
2023 Q1	$10	Hold	1	–	–	﹤0.01%	106
2022 Q4	$10	Hold	1	–	–	﹤0.01%	104
2022 Q3	$0	Hold	1	–	–	﹤0.01%	139
2022 Q2	$0	Hold	1	–	–	﹤0.01%	139
2022 Q1	$0	Buy	+1	New	+$10	﹤0.01%	137
2021 Q4	–	Sell	-1,000,000	Closed	-$9.95M	–	147
2021 Q3	$9.95M	Hold	1,000,000	–	–	0.19%	91
2021 Q2	$10.2M	Hold	1,000,000	–	–	0.18%	112
2021 Q1	$10M	Hold	1,000,000	–	–	0.21%	102
2020 Q4	$10.7M	Buy	+1,000,000	New	+$10.2M	0.21%	99

Deerfield Management's EUCRU Position: Q2 2023 in Review

Deerfield Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q2 2023, closing a stake of 1 share — an estimated $10 sold.

Deerfield Management first reported a position in EUCRU in Q4 2020 and held it in 9 quarters. The position peaked at $10.7M in Q4 2020. 0 funds tracked by Wall St. Rank hold EUCRU as of Q2 2023.

Deerfield Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q2 2023 after selling out during the quarter.
Deerfield Management sold 1 Eucrates Biomedical Acquisition Corp. Unit share in Q2 2023, an estimated $10.
Deerfield Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 9 quarters.
Deerfield Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $10.7M in Q4 2020.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q2 2023.

Based on Deerfield Management's 13F filing for Q2 2023, filed 14 Aug 2023.